EU F-Gas Regulation 2024/573: Strategic Guidance For MDI Manufacturers

The European Union’s intensified climate policy agenda is reshaping regulatory expectations across multiple industries including pharmaceutical manufacturers of metered dose inhalers (MDIs). With the implementation of Regulation (EU) 2024/573 on fluorinated greenhouse gases (F-gases), effective from February 2024, companies developing, manufacturing, and marketing MDIs must now carefully balance environmental sustainability, regulatory compliance, patient safety, and long-term product continuity.

Metered dose inhalers remain essential medicinal products for millions of patients managing asthma, COPD, and other chronic respiratory diseases. However, most MDIs currently rely on hydrofluorocarbon (HFC) propellants such as HFA-134a and HFA-227ea which are high-global warming potential (GWP) greenhouse gases.

This comprehensive guide by Maven Regulatory Solutions explains the strategic impact of EU F-Gas Regulation 2024/573 on MDI manufacturers, including HFC quota requirements, low-GWP transition strategies, EMA regulatory considerations, labeling obligations, lifecycle management implications, and future compliance expectations.

Understanding EU F-Gas Regulation 2024/573

Regulation (EU) 2024/573 forms part of the European Union’s broader climate neutrality strategy under:

• The European Green Deal 
• The Kigali Amendment to the Montreal Protocol 
• EU climate reduction targets for 2050 

The regulation aims to significantly reduce emissions of fluorinated greenhouse gases across the EU economy.

Although pharmaceutical MDIs account for only a relatively small proportion of total EU HFC consumption, the pharmaceutical sector is now formally integrated into the EU’s broader HFC reduction framework.

Importantly, the regulation also recognizes the critical public health importance of inhaled medicines and introduces phased implementation mechanisms to protect uninterrupted patient access.

Why the EU F-Gas Regulation Matters to MDI Manufacturers

Most traditional MDIs rely on HFC propellants because they:

• Deliver reliable aerosol performance 
• Support does consistency 
• Maintain product stability 
• Enable rapid pulmonary drug delivery 

However, these HFC propellants contribute to greenhouse gas emissions due to their high global warming potential.

The regulation therefore creates a dual regulatory challenge:

Manufacturers Must Now Balance

• Environmental sustainability 
• Medicinal product quality 
• EMA regulatory compliance 
• Clinical performance consistency 
• Supply continuity 
• Lifecycle management planning 

This convergence of environmental and pharmaceutical regulation represents a major strategic shift for respiratory product manufacturers.

Key Objectives of Regulation (EU) 2024/573 for MDIs

The regulation aims to:

• Reduce overall EU HFC emissions 
• Encourage development of low-GWP inhaler technologies 
• Preserve patient access to essential respiratory medicines 
• Promote sustainable pharmaceutical innovation 
• Align environmental and medicinal regulatory systems 
• Create predictable transition pathways for manufacturers 

Inclusion of MDIs in the EU HFC Quota System

For the first time, HFCs used in MDIs are explicitly incorporated into the EU HFC quota system.

What Is the HFC Quota System?

The quota system limits the amount of fluorinated greenhouse gases that can be placed on the EU market, expressed as:

CO₂-Equivalent Values

Quota allocation directly impacts the availability of HFC propellants for inhaler manufacturing.

Phased Transition Approach for Pharmaceutical Manufacturers

Recognizing the complexity of reformulating inhaled medicines, the EU introduced a health-sensitive transition framework.

This phased model is designed to provide sufficient time for:

• Product reformulation 
• Clinical bridge studies 
• Stability assessments 
• Regulatory approvals 
• Supply chain adaptation 

Strategic Implications for MDI Manufacturers

Manufacturers must now proactively manage:

• Long-term HFC availability 
• Quota allocation forecasting 
• Propellant sourcing strategies 
• Regulatory lifecycle planning 
• Portfolio sustainability assessments 

Key Strategic Consideration

HFC reference values are recalculated every three years.

This makes active monitoring of the:

EU F-Gas Portal

critical for long-term supply planning and quota management.

Low-GWP & Sustainable Inhaler Development

The regulation strongly encourages innovation toward environmentally improved inhalers.

Priority Areas Include

• Lower-GWP HFC alternatives 
• HFC-152a transition programs 
• Non-fluorinated propellant systems 
• Improved aerosol efficiency 
• Sustainable device engineering 
• Reduced carbon footprint packaging 

Manufacturers investing early in sustainable respiratory technologies may gain both regulatory and commercial advantages.

Regulatory Alignment with EMA Requirements

Despite environmental pressures, MDIs remain medicinal products regulated under stringent pharmaceutical standards.

Any propellant or formulation modification may require:

• Pharmaceutical quality assessments 
• Device compatibility evaluations 
• Clinical bridge studies 
• Stability data generation 
• Comparative performance testing 
• Regulatory variations or marketing authorization updates 

EMA & EU Coordination for Sustainable Inhalers

Regulation (EU) 2024/573 encourages closer coordination between:

• European Commission 
• EMA 
• EU Member States 
• Environmental authorities 

The goal is to facilitate smoother regulatory pathways for environmentally improved inhalers.

Potential regulatory advantages may include:

• Streamlined scientific advice 
• Optimized variation pathways 
• Lifecycle management flexibility 
• Earlier regulatory engagement opportunities 

Mandatory MDI Labeling Requirements 

All MDIs containing fluorinated greenhouse gases must comply with Article 12 labeling requirements under Regulation (EU) 2024/573.

Required Labeling Elements

Promotional & Advertising Requirements

If the propellant used has:

GWP ≥150

the same fluorinated gas information must also appear in:

• Promotional materials 
• Advertising content 
• Product communications 

This expands compliance obligations beyond packaging alone.

Bulk Propellant Container Requirements

Manufacturing-scale HFC containers must also include:

• Quota-related labeling 
• Applicable exemption wording 
• Traceability information 
• Compliance declarations 

Supply chain documentation requirements are becoming increasingly stringent.

Compliance Obligations Beyond Labeling

MDI manufacturers must comply with several operational obligations under the new regulation.

Key Requirements Include

• Annual HFC reporting via the EU F-Gas Portal 
• Independent verification of submitted data 
• Five-year documentation retention 
• Import/export traceability 
• EU Single Window Environment compliance 
• Recovery and handling obligations 
• Supply chain conformity oversight 

Non-compliance may trigger:

• Financial penalties 
• Quota restrictions 
• Product withdrawal 
• Market access limitations 
• Member State enforcement actions 

Product Lifecycle & Regulatory Change Management

Environmental transition initiatives may trigger complex pharmaceutical lifecycle changes.

Common Regulatory Activities Include

• Type IA/IB/II variations 
• Device change submissions 
• Stability program updates 
• Manufacturing process validation 
• Packaging updates 
• Labeling revisions 
• Clinical comparability assessments 

Early lifecycle planning is essential to avoid supply disruptions.

Impact on Supply Chain & Manufacturing Strategy

The regulation also affects:

• Propellant suppliers 
• Contract manufacturers 
• Device component suppliers 
• Packaging systems 
• Distribution planning 

Manufacturers should evaluate:

• Supplier diversification 
• Long-term HFC sourcing agreements 
• Inventory management strategies 
• Quota contingency planning 

ESG & Sustainability Considerations

Environmental compliance is increasingly linked to:

• ESG performance metrics 
• Investor expectations 
• Corporate sustainability reporting 
• Public procurement evaluations 
• Market reputation 

Low-GWP inhaler development may strengthen:

• Sustainability positioning 
• Market differentiation 
• Long-term commercial competitiveness 

Common Compliance Challenges for MDI Manufacturers

Organizations frequently encounter challenges involving:

• Propellant transition feasibility 
• EMA variation complexity 
• Clinical bridging requirements 
• Device compatibility issues 
• Quota forecasting uncertainty 
• Labeling implementation 
• Supply continuity risk 
• Cross-functional coordination 

Proactive regulatory strategy significantly reduces transition risk.

Future Trends in Sustainable Inhaler Regulation

Emerging trends include:

• Expansion of low-GWP inhaler pipelines 
• Increased carbon footprint disclosure expectations 
• Stronger ESG-linked healthcare procurement 
• Greater lifecycle flexibility for green reformulations 
• Increased global alignment on inhaler sustainability 
• Enhanced digital environmental reporting systems 

The future of respiratory medicines is becoming increasingly sustainability driven.

Quick Facts

• Regulation (EU) 2024/573 became effective in February 2024 
• MDIs are formally included in the EU HFC quota system 
• Mandatory labeling requirements apply from 1 January 2025 
• MDIs are not banned under the regulation 
• HFC quotas are recalculated every three years 
• Low-GWP inhaler technologies are strongly encouraged 
• EMA regulatory approvals remain essential for reformulated products 

Why Compliance Matters

Organizations failing to comply with EU F-Gas requirements may face:

• Quota limitations 
• Market access restrictions 
• Regulatory enforcement actions 
• Product withdrawal risk 
• Supply disruptions 
• Increased compliance costs 
• Reputational harm 

A proactive sustainability and lifecycle management strategy is essential for long-term commercial continuity.

How Maven Regulatory Solutions Supports MDI Manufacturers

Our Services

• EU F-Gas regulatory strategy 
• EMA lifecycle management planning 
• MDI variation support 
• Sustainability transition assessments 
• Labeling & artwork compliance 
• HFC quota strategy consulting 
• Regulatory gap assessments 
• Supply chain compliance support 
• ESG regulatory integration 
• Global respiratory product compliance consulting 

Why Choose Maven

• Deep pharmaceutical regulatory expertise 
• Strong respiratory product experience 
• Integrated environmental & medicinal compliance approach 
• Lifecycle management capabilities 
• Science-driven regulatory strategies 
• Up-to-date EU regulatory intelligence 

Our approach ensures:

• Sustainable compliance planning 
• Reduced transition risk 
• Faster regulatory alignment 
• Supply continuity protection 
• Long-term market competitiveness 

Need Support Navigating EU F-Gas Regulation 2024/573?

Whether you are assessing low-GWP transition strategies, planning EMA lifecycle submissions, updating labeling, or managing HFC quota compliance, Maven Regulatory Solutions can help simplify your regulatory pathway.

Contact Maven Regulatory Solutions For:

• EU F-Gas compliance strategy 
• EMA lifecycle management support 
• MDI variation planning 
• Sustainable inhaler transition consulting 
• Labeling compliance updates 
• HFC quota planning 
• ESG regulatory integration 
• Global respiratory product compliance support 

Visit Maven Regulatory Solutions to speak with our pharmaceutical regulatory experts today.

Conclusion

EU F-Gas Regulation 2024/573 represents a major regulatory transformation for pharmaceutical MDI manufacturers. By integrating environmental sustainability into the broader medicinal product lifecycle, the regulation creates both operational challenges and strategic opportunities for the respiratory sector.

Organizations that proactively align environmental compliance, lifecycle planning, regulatory strategy, and sustainable innovation will be best positioned to maintain patient access, secure long-term market continuity, and strengthen competitive advantage in the evolving EU healthcare landscape.

Maven Regulatory Solutions partners with pharmaceutical organizations to support sustainable respiratory product compliance through strategic regulatory planning, lifecycle management, and environmental regulatory expertise.

Frequently Asked Questions 

Q1. Are MDIs banned under EU F-Gas Regulation 2024/573?

No. MDIs are recognized as essential medicinal products and are not subject to outright bans.

Q2. When do the new labeling requirements become mandatory?

The labeling obligations apply from 1 January 2025.

Q3. Will reformulated inhalers require EMA approval?

Yes. Any propellant or formulation change requires appropriate regulatory assessment and approval.

Q4. What are low-GWP inhalers?

These are inhalers using propellants with significantly lower global warming potential compared to traditional HFCs.

Q5. How often are EU HFC quotas recalculated?

HFC reference values are recalculated every three years.

Q6. What are the risks of non-compliance?

Manufacturers may face penalties, quota restrictions, market access limitations, and supply disruptions.

Q7. How can Maven support MDI manufacturers?

Maven provides lifecycle strategy, EMA variation support, environmental compliance consulting, labeling review, and sustainable inhaler transition planning.